,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'breast', 'destiny-breast04']
trastuzumab deruxtecan versus tpc in her2-low unresectable and/or metastatic #breastcancer destiny-breast04 study. this is the future, now. #asco22 #oncoalerttoptweet #oncoalert 
Associate Professor, Florence University, Italy. Clinical Oncologist with focus on breast, radiation, research. Opinions are my own. RT not endorsement.